Here, we sought to determine if ZOL/IL-2-enhaced responses of Vγ2Vδ2 T effectors, CD4 + Th1, CD8 + T effectors and Foxp3+ Tregs could lead to milder MDR-TB pathology or lesions. The gene discussed is CD8A; the disease is tuberculosis.